An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
Man Xing,
Gaowei Hu,
Xiang Wang,
Yihan Wang,
Furong He,
Weiqian Dai,
Xinyu Wang,
Yixin Niu,
Jiaojiao Liu,
Hui Liu,
Xiaoyan Zhang,
Jianqing Xu,
Qiliang Cai,
Dongming Zhou
Affiliations
Man Xing
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University
Gaowei Hu
MOE&NHC&CAMS Key Laboratory of Medical Molecular, Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University
Xiang Wang
Shanghai Public Health Clinical Center, Fudan University
Yihan Wang
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University
Furong He
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University
Weiqian Dai
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University
Xinyu Wang
MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University
Yixin Niu
Shanghai Public Health Clinical Center, Fudan University
Jiaojiao Liu
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University
Hui Liu
Chengdu Kanghua Biological Products Co., Ltd
Xiaoyan Zhang
Shanghai Public Health Clinical Center, Fudan University
Jianqing Xu
Shanghai Public Health Clinical Center, Fudan University
Qiliang Cai
MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University
Dongming Zhou
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University
Abstract Despite prolonged surveillance and interventions, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses continue to pose a severe global health burden. Thus, we developed a chimpanzee adenovirus-based combination vaccine, AdC68-HATRBD, with dual specificity against SARS-CoV-2 and influenza virus. When used as a standalone vaccine, intranasal immunization with AdC68-HATRBD induced comprehensive and potent immune responses consisting of immunoglobin (Ig) G, mucosal IgA, neutralizing antibodies, and memory T cells, which protected the mice from BA.5.2 and pandemic H1N1 infections. When used as a heterologous booster, AdC68-HATRBD markedly improved the protective immune response of the licensed SARS-CoV-2 or influenza vaccine. Therefore, whether administered intranasally as a standalone or booster vaccine, this combination vaccine is a valuable strategy to enhance the overall vaccine efficacy by inducing robust systemic and mucosal immune responses, thereby conferring dual lines of immunological defenses for these two viruses.
